Qilu Pharmaceutical Secures Clinical Approvals for Five Class 1 New Drugs, Advancing in Trispecific Antibodies and ADC Platforms

Recently, Qilu Pharmaceutical has received consecutive clinical approvals for five Class 1 new drugs, frequently reporting good news in the field of innovative drug development.

In terms of specific drugs,QLS5132 for InjectionAs the first ADC drug targeting CLDN6 approved for clinical use in China, its significance is extraordinary. CLDN6 is abnormally expressed in various solid tumors and represents a highly promising target for cancer treatment. The emergence of QLS5132 fills the gap in innovative drug development for this target in China, breaking the technological lead of foreign countries in this cutting-edge field and opening a new path for targeted cancer therapy in China.

QLS4131 InjectionThe progress is equally remarkable. As a BCMA/GPRC5D/CD3 trispecific antibody drug, it has already made a name for itself in the field of multiple myeloma treatment. The recent approval for clinical trials of systemic lupus erythematosus further expands its application scope. This strategic layout reflects Qilu Pharmaceutical's deep exploration into the treatment of immune-related diseases. With immunotherapy gradually becoming a focal point in the pharmaceutical industry, the dual-indication coverage of QLS4131 gives it potential in both hematological malignancies and autoimmune diseases.

QLS1304 TabletsThe clinical approval focuses on the treatment of advanced solid tumors. The robust efficacy demonstrated in ER+/HER2- breast cancer models highlights its potential in overcoming refractory tumors. Obtaining the FDA Fast Track designation in the United States is a strong recognition of its R&D capabilities and drug value.

QLS12010 Capsules and QLS1209 TabletsThe approval for clinical trials respectively demonstrate Qilu Pharmaceutical's technological innovation in the fields of autoimmune disease and advanced solid tumor treatment.

QLS12010 Shows Promising Preclinical Results for Common and Difficult-to-Treat Autoimmune Diseases Like Atopic Dermatitis, Bringing Hope to Hundreds of Millions of Patients and Demonstrating the Company’s Commitment to Meeting Public Health Needs.

QLS1209, as the first highly efficient and selective inhibitor of its kind in China targeting a specific gene alteration in tumor patients, demonstrates a precise research and development strategy. This approach not only aligns with the modern trend of personalized and precise cancer treatment but also reflects Qilu Pharmaceutical's keen insight into the needs of细分 patient populations.

Overall, the approval for clinical trials of Qilu Pharmaceutical's five Class 1 new drugs this time is backed by its robust R&D system.Over the years, Qilu Pharmaceutical has consistently invested a high proportion of its resources into research and development, establishing a complete innovation chain from basic research to clinical translation. Its deep accumulation in multidisciplinary cross-fields such as biotechnology and pharmaceutical chemistry has provided continuous momentum for new drug development.

At the same time, this also reflects the forward-looking nature of the company's strategic layout.Qilu Pharmaceutical accurately addresses unmet clinical needs in major disease areas such as oncology and autoimmune diseases. By proactively deploying emerging targets and cutting-edge technologies, such as ADCs and tri-specific antibodies, the company has successfully transformed from a generic drug giant to a leader in innovative drug development.

From an industry perspective, this achievement of Qilu Pharmaceutical has injected a strong boost into China's pharmaceutical innovation.Against the backdrop of national encouragement for pharmaceutical innovation and strong policy support, the successful case of Qilu Pharmaceutical will inspire more pharmaceutical companies in China to increase R&D investment and bravely explore innovative drug development.

Conclusion: The approval of five Class 1 new drugs for clinical use by Qilu Pharmaceutical is a milestone for the company and a new starting point for the industry. The R&D strength, strategic layout, and innovative spirit behind it are worth in-depth study and reference, indicating that China's pharmaceutical industry will take more solid steps on the road to innovation.

Reference Source: https://mp.weixin.qq.com/s/GmKBWGsvKhxbj--i0a74sA